Cardinal Health (CAH) has raised its fiscal 2024 guidance range for non-GAAP earnings per share to $6.75 to $7.00, from prior guidance range of $6.50 to $6.75. The guidance includes an update to the Pharmaceutical segment profit outlook to 7% to 9% growth, from prior guidance range of 4% to 6% growth. Pharmaceutical segment revenue growth is projected in a range of 10% to 12%.
For the fiscal 2024-26 period, Cardinal Health targets non-GAAP EPS growth of 12% to 14%, CAGR.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.